{"id":55763,"date":"2026-01-29T13:50:40","date_gmt":"2026-01-29T05:50:40","guid":{"rendered":"https:\/\/flcube.com\/?p=55763"},"modified":"2026-01-29T13:50:41","modified_gmt":"2026-01-29T05:50:41","slug":"biogens-litifilimab-secures-fda-breakthrough-therapy-designation-for-lupus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55763","title":{"rendered":"Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus"},"content":{"rendered":"\n

Biogen Inc.<\/strong> (NASDAQ:\u202fBIIB<\/a>) announced that its investigational litifilimab<\/strong> has received Breakthrough Therapy Designation (BTD)<\/strong> from the U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of cutaneous lupus erythematosus (CLE)<\/strong>, a chronic autoimmune skin disease with no approved targeted therapies.<\/p>\n\n\n\n

Regulatory Milestone & Drug Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Biogen Inc. (NASDAQ:\u202fBIIB)<\/td><\/tr>
Drug<\/strong><\/td>Litifilimab<\/td><\/tr>
Designation<\/strong><\/td>FDA Breakthrough Therapy Designation (BTD)<\/td><\/tr>
Indication<\/strong><\/td>Cutaneous lupus erythematosus (CLE)<\/td><\/tr>
Mechanism<\/strong><\/td>First\u2011in\u2011class humanized IgG1 mAb targeting BDCA2<\/td><\/tr>
Key Innovation<\/strong><\/td>First targeted therapy for CLE; no approved treatments currently exist<\/td><\/tr>
Development Stage<\/strong><\/td>BTD based on Phase\u202fII data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mechanism of Action & Clinical Differentiation<\/h2>\n\n\n\n